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Abstract
Background: Astrocytomas are the most common primary brain tumors distinguished into four histological grades.
Molecular analyses of individual astrocytoma grades have revealed detailed insights into genetic, transcriptomic and
epigenetic alterations. This provides an excellent basis to identify similarities and differences between astrocytoma
grades.
Methods: We utilized public omics data of all four astrocytoma grades focusing on pilocytic astrocytomas (PA I),
diffuse astrocytomas (AS II), anaplastic astrocytomas (AS III) and glioblastomas (GBM IV) to identify similarities and
differences using well-established bioinformatics and systems biology approaches. We further validated the
expression and localization of Ang2 involved in angiogenesis using immunohistochemistry.
Results: Our analyses show similarities and differences between astrocytoma grades at the level of individual genes,
signaling pathways and regulatory networks. We identified many differentially expressed genes that were either
exclusively observed in a specific astrocytoma grade or commonly affected in specific subsets of astrocytoma grades
in comparison to normal brain. Further, the number of differentially expressed genes generally increased with the
astrocytoma grade with one major exception. The cytokine receptor pathway showed nearly the same number of
differentially expressed genes in PA I and GBM IV and was further characterized by a significant overlap of commonly
altered genes and an exclusive enrichment of overexpressed cancer genes in GBM IV. Additional analyses revealed a
strong exclusive overexpression of CX3CL1 (fractalkine) and its receptor CX3CR1 in PA I possibly contributing to the
absence of invasive growth. We further found that PA I was significantly associated with the mesenchymal subtype
typically observed for very aggressive GBM IV. Expression of endothelial and mesenchymal markers (ANGPT2, CHI3L1)
indicated a stronger contribution of the micro-environment to the manifestation of the mesenchymal subtype than
the tumor biology itself. We further inferred a transcriptional regulatory network associated with specific expression
differences distinguishing PA I from AS II, AS III and GBM IV. Major central transcriptional regulators were involved in
brain development, cell cycle control, proliferation, apoptosis, chromatin remodeling or DNA methylation. Many of
these regulators showed directly underlying DNA methylation changes in PA I or gene copy number mutations in AS
II, AS III and GBM IV.
Conclusions: This computational study characterizes similarities and differences between all four astrocytoma
grades confirming known and revealing novel insights into astrocytoma biology. Our findings represent a valuable
resource for future computational and experimental studies.
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Background
Astrocytomas are the most common primary brain
tumors in the course of life [1]. Molecular origins of astro-
cytomas are not fully understood. Different studies have
identified tumorigenic cells with stem-cell-like proper-
ties suggesting that astrocytomas originate from neural
stem cells [2, 3]. Astrocytomas are classified by the World
HealthOrganization (WHO) grading system into four his-
tological grades of increasing malignancy [4]. Here, we
focus on a comparative analysis of the most frequently
occurring astrocytomas (pilocytic astrocytoma, diffuse
astrocytoma, anaplastic astrocytoma, glioblastoma) of dif-
ferent degrees of aggressiveness to assess for similarities
and differences at the level of individual genes, signaling
pathways, molecular subtypes and regulatory networks.
This is highly important to better understand the devel-
opment of specific astrocytomas.
The pilocytic astrocytoma WHO grade I (PA I) is a
very slowly growing benign astrocytoma. PA I is the most
commonly diagnosed brain tumor in childhood and ado-
lescence [5]. The ten-year overall survival rate of PA I
patients is greater than 95% [1]. The treatment of choice
for PA I is gross total resection, but PA I tumors that
are inoperable or only partly accessible by surgery repre-
sent a therapeutic challenge often showing a serve clinical
course [6, 7]. Recent studies have indicated that PA I is
predominantly a single-pathway disease driven by muta-
tions affecting the MAPK pathway [5, 7]. In addition,
PA I can also display histological features of glioblas-
toma (GBM IV) includingmicrovascular proliferation and
necrosis, but in contrast to GBM IV, these features are
not directly associated with increased malignancy of PA I
[8]. In rare cases, progression of PA I to more malignant
astrocytomas has been observed [9].
In contrast to PA I, astrocytomas of WHO grade II to
IV almost exclusively occur in adults. These astrocytomas
are characterized by a diffuse infiltrating growth into the
surrounding brain tissue that is absent in PA I. Therefore,
AS II, AS III and GBM IV are also referred to as diffuse
gliomas.
The diffuse astrocytoma WHO grade II (AS II) is a
slowly growing invasive semi-benign astrocytoma. AS II
is frequently diagnosed in young adults between 20 and
45 years with an average age of 35 years [10]. The dif-
fuse invasive growth of AS II with no clearly identifiable
boarder between tumor and normal tissue makes com-
plete surgical resection almost impossible [11]. Recur-
rences of tumors are observed in most patients after few
years with progression to more malignant AS III or GBM
IV in many cases [12–14]. The median survival of AS II
patients is between five to eight years [15].
The anaplastic astrocytoma WHO grade III (AS III) is
an invasively and faster growing malignant astrocytoma.
AS III is characterized by increased mitotic activity and
more variable size and shape of tumor cells in comparison
to AS II [4]. The average age of patients diagnosed with AS
III is 45 years. When possible, surgical resection followed
by radiotherapy and/or chemotherapy is the treatment of
choice. Similar to AS II, progression of AS III to the most
malignant GBM IV is frequently observed [13, 14]. The
overall five-year survival rate of AS III patients is 24% [16]
and the median survival is between one to four years [17].
The glioblastomaWHO grade IV (GBM IV) is the most
malignant astrocytoma [4]. GBM IV is a very fast inva-
sively growing tumor. In contrast to AS III, GBM IV also
shows necrosis and/or vascular proliferation. Two genet-
ically distinct GBM IV classes are known: (i) secondary
GBMs that develop progressively over several years from
less malignant AS II or AS III, and (ii) primary GBMs
that develop within fewmonths without prior occurrences
of lower grade astrocytomas [12, 13]. Only about 5% of
GBM IV cases are secondary GBMs [18]. Patients diag-
nosed with a secondary GBM are on average younger than
primary GBM patients (45 vs. 62 years) [12]. Primary and
secondary GBMs are histologically indistinguishable. IDH
mutations in secondary GBMs enable a distinction from
primary GBMs at the molecular level [19]. These IDH1
or IDH2 mutations are already present in less malignant
AS II and AS III [20]. The treatment of choice is surgical
resection in combination with radiation and chemother-
apy. This intensive treatment increases the average sur-
vival of GBM IV patients to about 15 months [21] com-
pared to 13 weeks for surgery alone [22]. Less than 5% of
patients survive longer than five years [18].
Over the last years, rapid advances in experimental
technologies have enabled detailed molecular analyses of
large cohorts of different types of astrocytomas that pro-
vided new insights into pathological mechanisms [5, 7, 19,
23, 24], molecular subtypes [25–27], alterations of signal-
ing pathways [23, 24, 28], or activities of transcriptional
regulatory networks [29–33]. Other studies have focused
on the characterization of differences between astrocy-
toma grades to better understand pathogenic impacts of
molecular alterations. Differential expression of immune
defense genes in PA I in comparison to AS II with poten-
tial indications toward benign behavior of PA I have been
reported [34]. Characteristic expression of anti-migratory
genes has been found in PA I in comparison to AS II,
AS III and GBM IV putatively contributing to the com-
pact, well-circumscribed growth of PA I in contrast to
the infiltrative growth of higher-grade astrocytomas [35].
Further molecular markers distinguishing PA I from AS
II, AS III and GBM IV have been reported in [36, 37].
A comparative analysis of AS II, AS III and GBM IV
has revealed greater regulatory network dysregulation
associated with increasing astrocytoma grade [33]. Addi-
tionally, mutational patterns associated with the origin
and chemotherapy therapy-driven evolution of recurrent
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secondary gliomas have recently been reported [14]. All
these andmany other studies have greatly contributed to a
better understanding of astrocytoma development hope-
fully contributing to urgently needed new therapeutic
strategies in the near future.
However, most studies have only focused on the iden-
tification of differences between astrocytoma grades.
This is of course very important to better understand
molecular mechanisms associated with aggressiveness of
different astrocytoma grades and to reveal novel grade-
specific therapeutic targets. On the other hand, still only
little is known about commonly altered genes, shared
molecular subtypes, common alterations in signaling or
metabolic pathways, or activities of major transcriptional
regulators. More detailed information about these reg-
ulatory mechanisms is also very important to further
increase our knowledge about astrocytoma development
and may reveal unexpected similarities between astrocy-
toma grades.
Here, we utilize publicly available molecular data of
astrocytomas to systematically characterize similarities
and differences of all four astrocytoma grades. In more
detail, we characterize transcriptional alterations at the
level of individual genes and known molecular path-
ways. We analyze all four astrocytoma grades for their
association with known molecular subtypes and utilize
immunohistochemistry to validate Ang2 as a marker gene
predicted to distinguish PA I and GBM IV from AS II and
AS III. We further determine a regulatory network that
distinguishes PA I from AS II, AS III and GBM IV reveal-
ing major transcriptional regulators and directly underly-
ing mutations putatively associated with pathobiological
differences.
Methods
No ethical approval was required for this study. All uti-
lized public omics data sets were generated by others who
obtained ethical approval.
Molecular data of PA I
We considered raw gene expression data of 49 PA I
and 9 normal cerebellum reference samples (5 fetal
and 4 adult samples) available from Gene Expression
Omnibus (GSE44971) [38]. We performed stringent qual-
ity controls of all expression arrays by reconstructing
the hybridization images. We removed three arrays with
slight hybridization artifacts. The remaining samples are
listed in Additional file 1: Table S1. All correspond-
ing microarrays were normalized using GCRMA [39]
with a design file from BrainArray (HGU133Plus2 ver-
sion 15.0.0). The resulting PA I gene expression data set
comprised 47 PA I samples and 8 corresponding normal
cerebellum references for which expression levels were
measured for 16,973 genes. We further also downloaded
processed DNA methylation profiles available for 38 of
the considered PA I samples (GSE44684) analyzed in [38].
Tumor-specific DNAmethylation profiles were compared
to DNA methylation profiles of normal cerebellum sam-
ples from four fetal and two adult probes. We refer to [38]
for more details. All PA I tumors were diagnosed in chil-
dren or young adults (Additional file 2: Figure S1) and
fulfill all editorial policies (ethical approval and consent,
standards of reporting, data availability).
Molecular data of AS II, AS III and GBM IV
We considered raw gene expression and gene copy num-
ber data of AS II, AS III, GBM IV and adult normal
brain references from epilepsy patients from the Repos-
itory for Molecular Brain Neoplasia Data (Rembrandt,
release 1.5.9) [40]. The non-tumor samples from Rem-
brandt were already used as references for the analysis of
AS II, AS III and GBM IV tumors in [41]. We again per-
formed stringent quality controls and removed all patient
or reference samples where expression or copy number
microarrays had hybridization artifacts. See Additional
file 1: Table S1 for considered samples. The remaining
gene expression samples were further normalized as pre-
viously described for PA I. This resulted in a gene expres-
sion data set that comprised 16 AS II, 17 AS III, 45 GBM
IV and 21 corresponding normal adult brain references
from epilepsy patients for which expression levels were
measured for 16,973 genes. Processing of corresponding
gene copy number data was more complex (Additional file
2: Text S1). The majority of tumors was diagnosed in older
adults. The age at diagnosis tended to increase with the
WHO grades of the tumors (Additional file 2: Figure S1).
All data sets fulfill the editorial policies (ethical approval
and consent, standards of reporting, data availability).
Identification of differentially expressed genes
We performed t-tests to identify under- and overex-
pressed genes for each type of astrocytoma (PA I, AS II,
AS III, GBM IV) under consideration of the correspond-
ing normal brain references. We corrected for multiple
testing by computing FDR-adjusted p-values (q-values) for
all genes [42] and considered for each type of astrocy-
toma all genes with q-values below 0.0001 as differentially
expressed in tumor compared to normal brain tissue. We
further used the sign of the average gene-specific log-ratio
of tumor versus normal to specify which of these genes
were under- (negative sign) and overexpressed (positive
sign) in each specific type of astrocytoma. See Additional
file 1: Table S2 for t-test results obtained for all four
astrocytoma grades. Further, we note that the considered
astrocytoma types represent a heterogeneous group of
tumors. PA I is often localized in the cerebellum of chil-
dren or young adults, whereas AS II, AS III and GBM
IV are mainly occurring in the cerebrum of adults. Thus,
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it is hard to specify a common normal brain reference
that would perfectly fit to all astrocytoma types with
respect to their different tumor locations and age inci-
dences. Therefore, we decided to analyze all astrocytomas
under consideration of the normal brain references that
were used in the corresponding initial publications (see
[38] for PA I and [40, 41] for AS II, AS III and GBM
IV). With the choice of these references we try to control
for the heterogeneity of the astrocytoma grades to iden-
tify differences in astrocytoma-specific gene expression
in comparison to the surrounding normal brain tissue in
which these tumors are typically diagnosed. That is, PA I
was analyzed with respect to normal cerebellum. Normal
brain references from epilepsy patients were considered
for the analysis of AS II, AS III and GBM IV. Note that this
choice of references does not exclude that some of the dif-
ferentially expressed genes that distinguish PA I from AS
II, AS III and GBM IV may only occur because of expres-
sion differences in the corresponding references. How-
ever, considering both references, we found a significant
positive correlation between average gene expression lev-
els of normal cerebellum and normal brain from epilepsy
patients (r = 0.874, P < 2.2 × 10−16). This indicates
that the majority of genes has very similar expression pro-
files in both astrocytoma type-specific references. Thus,
the used normal brain references should represent a good
compromise to account for the location- and age-specific
heterogeneity distinguishing PA I from AS II, AS III and
GBM IV.
Molecular subtype classification
We downloaded the Verhaak gene expression signatures
of 840 genes (ClaNC840_centroids.xls) available from [25]
to determine the similarity of each individual astrocytoma
to four known molecular subtypes (neural, proneural,
classical, mesenchymal). We identified that 757 of these
840 signature genes were also measured in each of our
PA I, AS II, AS III and GBM IV samples. For each of
these samples, we first computed for each of the 757 genes
its relative expression level (log2-ratio) in tumor com-
pared to its average expression in normal brain. Next, we
computed the correlations of these 757 sample-specific
expression levels with the corresponding expression lev-
els of the four molecular subtypes. We further tested if
the correlation of an individual sample with a specific sub-
type was significantly greater than zero (Pearson’s product
moment correlation test). We finally assigned each astro-
cytoma sample to the Verhaak-subtype with the greatest
significant positive correlation (P < 0.05).
Molecular signature distinguishing PA I from AS II, AS III
and GBM IV
We determined a molecular gene signature that distin-
guished PA I from AS II, AS III and GBM IV using
the previously identified differentially expressed genes. To
realize this, we considered each gene that was (i) under-
expressed in PA I but not in AS II, AS III or GBM IV, (ii)
unchanged in PA I but not in AS II, AS III or GBM IV, or
(iii) overexpressed in PA I but not in AS II, AS III or GBM
IV. Then, we considered this reversely and determined
each gene that was (iv) underexpressed in AS II, AS III or
GBM IV but not in PA I, (v) unchanged in AS II, AS III
or GBM IV but not in PA I, or (vi) overexpressed in AS II,
AS III or GBM IV but not in PA I. All genes that passed
one of these criteria showed characteristic expression dif-
ferences comparing PA I against AS II, AS III or GBM IV.
We further only focused on signature genes with strong
expression differences and removed all genes with an aver-
age gene expression difference below two comparing both
classes. This resulted in 1,089 signature genes distinguish-
ing PA I fromAS II, AS III and GBM IV. See Additional file
1: Table S3 for obtained signature genes and their average
gene expression log-ratios of tumor versus normal.
Signature-specific regulatory network inference
We considered gene-specific sub-network inference prob-
lems to derive a transcriptional regulatory network asso-
ciated with the expression of molecular signature genes
distinguishing PA I fromAS II, AS III and GBM IV. There-
fore, we focused on the expression levels of N = 1, 089
signature genes in our data set of in total D = 125
astrocytomas. For each signature gene i ∈ {1, . . . ,N}, we
assumed that its expression level eid in an astrocytoma




aji · ejd (1)
of the expression levels ejd of transcriptional regulators
j ∈ TF \ {i} that were part of the molecular signature that
distinguishes PA I from AS II, AS III and GBM IV. Here,
TF defines the subset of genes in the molecular signature
that were annotated as TFs (151 of 1,089). The expression
level eid of each gene i in an astrocytoma d is given by the
log2-ratio of the expression level of gene i in astrocytoma
d in comparison to the expression level of gene i in the cor-
responding average normal brain reference. The unknown
parameters of this signature gene-specific linear model
are given by ai := (aji)j∈TF\{i}. Each individual parame-
ter aji ∈ R quantifies the impact of the expression level of
regulator j on the expression level of signature gene i: (i)
aji < 0 specifies that TF j is a putative inhibitor of gene i,
(ii) aji > 0 defines that TF j is a putative activator of gene
i, and (iii) aji = 0 means that no dependency between j
and i exists. We used lasso (least absolute shrinkage and
selection operator) regression [43] in combination with
a recently developed significance test for lasso [44] to
estimate each aji and its corresponding significance for
Eq. (1). This enabled us to select themost relevant putative
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regulators of each signature gene (Additional file 1: Table
S4, P < 5×10−5). Details are provided in Additional file 2:
Text S2. We further validated the predictive power of the
obtained regulatory network on independent astrocytoma
data sets (Additional file 2: Text S4, Figure S7) and we
also evaluated the putative proportion of included direct
TF-target gene interactions (Additional file 2: Text S5,
Figure S8). All these validation studies clearly indicated
that the regulatory network included relevant TF-target
gene links to predict the expression levels of signature
genes based on the expression profiles of TFs.
Gene annotations
We utilized different public resources to create a compre-
hensive summary of cancer-relevant gene annotations for
the analysis of differentially expressed genes. This com-
prised genes annotated of TFs/cofactors, kinases, phos-
phatases, signaling pathway genes, metabolic pathway
genes, oncogenes, tumor suppressor genes, cancer census
genes, and genes essential for cell survival. Details and ref-
erences are provided in Additional file 1: Table S5. Addi-




Transcriptional alterations increase with WHO grade
We first globally analyzed PA I, AS II, AS III and GBM
VI and found that the number of differentially expressed
genes increased significantly with increasing WHO grade
(r = 0.92, P = 0.04, Pearson’s product moment cor-
relation). Corresponding statistics are shown in Fig. 1a
for each type of astrocytoma. Compared to PA I known
to have the best prognosis, AS II and AS III showed a
nearly two-fold increase in differentially expressed genes.
A nearly four-fold increase was observed for GBM IV
representing the most malignant astrocytoma. We also
observed that the number of overexpressed genes in PA
I was more than two-fold higher than the number of
underexpressed genes. This was much more balanced for
AS II and AS III. Similar to PA I, GBM IV also showed
clearly more over- than underexpressed genes. The global
tendencies remained highly similar but the numbers of
differentially expressed genes were clearly reduced when
we further restricted the identified genes to those with
strong expression changes of absolute log2-fold-changes
greater than two compared to normal brain (Fig. 1a).
Next, we analyzed the identified differentially expressed
genes in the context of functional categories or cellular
processes known to be involved in cancer. Therefore, we
first used data from different public resources to define
nine cancer-relevant categories containing genes that are
essential for cell survival, oncogenes, tumor suppres-
sor genes, cancer census genes, phosphatases, kinases,
metabolome genes, signaling pathway genes, and tran-
scriptional regulators (Additional file 1: Table S5). We
then determined for each category the overlap with the
differentially expressed genes identified for each type of
astrocytoma. Again, we found that the numbers of dif-
ferentially expressed genes in each category increased
significantly with the WHO grades (r > 0.91, P < 0.043
for all categories, Pearson’s product moment correla-
tion). A statistic representing the number of differentially
expressed genes in each of these categories for each type
of astrocytoma is shown in Fig. 1b. Genes essential for cell
survival, phosphatases, and kinases were only significantly
overrepresented in AS II, AS III and GBM IV. Onco-
genes were enriched in PA I, AS III and GBM IV, whereas
tumor suppressor genes were only enriched in AS III
and GBM IV. Additionally, cancer census genes [45] and
genes that were part of known cancer-relevant signaling
pathways were only significantly overrepresented in GBM
IV. Although not significantly enriched, we observed sev-
eral differentially expressed metabolic pathway genes,
even more differentially expressed cancer-relevant sig-
naling pathway genes, and many differentially expressed
transcriptional regulators in all astrocytoma grades with
numbers of affected genes again increasing from PA I to
GBM IV (Fig. 1b).
Finally, we further extended the previous analysis to
distinguish between under- and overexpressed genes
(Additional file 2: Figure S2). No enrichment of under-
expressed genes was observed for essential and sig-
naling pathway genes in all four astrocytoma grades.
Underexpressed genes annotated as oncogenes, tumor
suppressor genes, cancer census genes or transcrip-
tional regulators were significantly enriched in PA I.
Phosphatases and kinases were significantly overrepre-
sented among underexpressed genes in AS II, AS III and
GBM IV. Underexpressed metabolome genes were only
significantly enriched in GBM IV. Further, no signifi-
cant enrichment of overexpressed genes was observed
for phosphatases, kinases and metabolome genes in all
four astrocytoma grades. Overexpressed oncogenes were
significantly overrepresented in AS II and AS III. Tran-
scriptional regulators, tumor suppressors and cancer cen-
sus genes were significantly enriched for overexpressed
genes in AS II, AS III and GBM IV. Overexpressed signal-
ing pathway genes were significantly enriched in all four
astrocytoma grades.
Verhaak classification reveals strong association of PA I
with mesenchymal subtype
Classification of astrocytomas according to knownmolec-
ular subtypes is important to improve treatment decisions
and prognosis. Four major subtypes of GBM IV were first
revealed in [25] and later also identified in AS II and AS
III [27]. This has been widely applied to classify individual
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Fig. 1 Expression changes and functional categorization of differentially expressed genes for different astrocytoma grades. a, Number of
differentially expressed genes identified for each type of astrocytoma in comparison to normal brain references at an FDR of 0.0001. An additional
log-fold-change cutoff (LFC) of two was used for the first three categories to focus on genes with strong expression changes. b, Number of
differentially expressed genes annotated in selected functional categories: essential genes, oncogenes, tumor suppressor genes, cancer census
genes, phosphatases, kinases, metabolome pathway genes, signaling pathway genes, and transcriptional regulators (see Methods for details).
Significant enrichment of genes in a category within a tumor type is represented by ’*’ (P < 0.05) and ’**’ (P < 0.01) (Fisher’s exact test)
AS II, AS III and GBM IV tumors either as neural, proneu-
ral, classical or mesenchymal, but so far it has not been
tested if one or more of these subtypes are also associated
with PA I. Therefore, we used the Verhaak-classifier [25]
to compute the correlation between the given signature-
specific expression levels of the Verhaak-subtypes and the
corresponding gene expression levels of each individual
astrocytoma. Correlations of each individual PA I, AS II,
AS III and GBM IV tumor with the four Verhaak-subtypes
are shown in Fig. 2 and provided in Additional file 1:
Table S6.
Interestingly, all PA I tumors showed very homogeneous
correlation profiles resulting in a significant association
with the mesenchymal subtype (Fig. 2a, r > 0.14, P <
2.14 × 10−5 for all PA I, Pearson’s product moment cor-
relation). We further confirmed this observation for an
independent PA I cohort [46], where again 40 of 41 PA I
tumors were significantly correlated with the mesenchy-
mal subtype (Additional file 2: Figure S3, r > 0.17, P <
4.5 × 10−7 for all PA I). The mesenchymal subtype was
observed to be strongly associated with cultured astroglial
cells that showed high expression of microglia markers
[25]. Additionally, PA I was reported to show increased
microglia proliferation in comparison to AS II, AS III and
GBM IV [47]. This indicates that the strong association of
PA I with the mesenchymal subtype may at least in part
be explained with the role of the microglia. To analyze
this, we first identified that 16 microglia/macrophage
marker genes from [48] were part of the Verhaak-classifier
(Additional file 1: Table S7). Next, we used these genes and
found a significant positive correlation between the aver-
age expression levels of microglia/macrophage marker
genes in PA I and corresponding mesenchymal subtype
expression levels from Verhaak (r = 0.56, P < 0.013).
This trend was also observed for AS II, AS III and
GBM IV average marker expression profiles (r > 0.58,
P < 0.009) and also for individual AS II, AS III and
GBM IV tumors that were not classified as mesenchymal
(Additional file 1: Table S7). Thus, additional pathobio-
logical features such as microvascular proliferation and
necrosis most likely contribute to the strong association of
PA I with mesenchymal subtype.
Microvascular proliferation and necrosis were
described as common features of PA I and GBM IV [8].
Also increased necrosis was reported for the mesenchy-
mal subtype [25]. We observed that ANGPT2 (alias
ANG2), an endothelial cell marker involved in angiogen-
esis [49], had significantly higher expression levels in PA
I and GBM IV than in AS II or AS III in comparison to
normal brain (Additional file 1: Table S2). Interestingly,
these astrocytoma grade-specific expression profile of
ANGPT2 was highly correlated with that of the endothe-
lial cell marker THBD (r = 0.86, P = 0.07), which is part
of the Verhaak signature. In contrast to THBD, ANGPT2
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Fig. 2 Classification of individual astrocytoma patients according to known molecular subtypes. Classification of PA I, AS II, AS III and GBM IV patients
according to molecular subtypes (Neural, Proneural, Classical, Mesenchymal) defined by Verhaak [25]. Correlations between patient-specific
expression levels of Verhaak signature genes and each of the four subtype-specific Verhaak signatures were computed for each patient. Colored
curves represent the obtained patient-specific correlations. A grey dot within each patient-specific curve highlights the assigned Verhaak-subtype
to which the underlying patient had the strongest positive correlation. The subfigures a to d show the results for individual PA I, AS II, AS III, and
GBM IV patients
is not part of the Verhaak signature, but this positive
correlation indicates that microvascular proliferation and
necrosis may contribute to the mesenchymal classifica-
tion obtained for all PA I and many GBM IV tumors. To
further test this, we confirmed by immunohistochemistry
that PA I and GBM IV showed Ang2-positive endothelial
cells (protein expression) in regions with activated blood
vessels, a feature that was largely absent in AS II and
AS III (Additional file 2: Figure S4, Text S3). We also
found that the expression of the mesenchymal marker
CHI3L1 [25] was highly correlated with the expression of
ANGPT2 (r = 0.89, P < 0.06). Thus, this all indicates
that several different factors contribute to the strong
association of PA I with the mesenchymal subtype. In
addition, the micro-environment may have a stronger
contribution on these subtype-characteristics than the
distinct aggressiveness of mostly benign PA I and highly
malignant GBM IV tumor cells.
The Verhaak-classification of AS II, AS III and GBM
IV was clearly more heterogeneous revealing few proneu-
ral, some classical and many mesenchymal astrocytomas
in each class (Fig. 2b–d). The neural subtype was clearly
underrepresented in the considered cohorts. Only one PA
I tumor from [46] was classified as neural with marginally
higher significance than for mesenchymal (Additional file
1: Table S6).
The Verhaak-classification scheme has been further
refined by a hypermethylator subtype predominantly
observed within a subgroup of proneural astrocytomas
[26]. A specific mutation of IDH1 frequently found in AS
II, AS III and secondary GBM IV has been shown to be a
key driver of this subtype [50]. We used the gene expres-
sion signature of the hypermethylator subtype (Table 2 in
[26]) to determine the correlation of each of our astrocy-
toma samples with this subtype. As expected, PA I and
the majority of our GBM IV tumors, both typically lack-
ing IDH1 mutations, were negatively correlated with the
hypermethylator subtype, whereas the majority of AS II
and AS II showed positive correlations (Additional file 2:
Figure S5).
Specific patterns of differential expression characterize
similarities and differences of different astrocytomas
Besides the observed molecular heterogeneity between
and within the different astrocytoma types, we next aimed
at the identification of core sets of genes that were
commonly under- or overexpressed in different astrocy-
toma subsets. We therefore considered all differentially
expressed genes identified for PA I, AS II, AS III and GBM
IV and utilized Venn diagrams to quantify the numbers
of genes that were exclusively present in specific subsets
of these types of astrocytomas (Fig. 3). Expression states of
Seifert et al. BMC Cancer  (2015) 15:952 Page 8 of 22
Fig. 3 Comparison of genes with altered expression in different astrocytoma grades. Venn diagrams were used to quantify commonalities and
differences between differentially expressed genes identified for each type of astrocytoma in comparison to normal brain. a, Underexpressed genes.
b, Overexpressed genes. c, Underexpressed cancer signaling pathway genes. d, Overexpressed cancer signaling pathway genes
individual genes for all types of astrocytomas are provided
in Additional file 1: Table S2. We observed that the num-
ber of commonly under- or overexpressed genes in AS II,
AS III and GBM IV were substantially increased in com-
parison to any intersection of PA I with two more malig-
nant astrocytoma grades (Fig. 3a–b, e.g. 1140 under- and
831 overexpressed genes in common between AS II, AS III
and GBM IV vs. 27 under- and 62 overexpressed genes in
common between PA I, AS II and GBM IV). Additionally,
AS II and AS III alone also shared many more commonly
under- or overexpressed genes with GBM IV than with PA
I (e.g. 270 under- and 203 overexpressed genes in com-
mon between AS II and GBM IV vs. 2 under- and 12
overexpressed genes in common between AS II and PA
I). Interestingly, there was a strong exclusive overlap of 86
under- and 305 overexpressed genes in common between
PA I and GBM IV that contained substantially more genes
than observed between PA I and AS II or PA I and AS
III. These different general tendencies were also observed
when we exclusively focused on known cancer signaling
pathway genes (Fig. 3c–d).
We further analyzed which genes were commonly
under- or overexpressed in each of the four specific astro-
cytoma grades and in different subsets of astrocytoma
grades (Fig. 3). We also investigated which molecular
processes were regulated by subset-specific genes using
GOrilla [51]. Since there were so many transcriptomic
changes comparing astrocytomas to normal brain tissue,
we only report details for some well-known or potentially
interesting genes. We further refer to Additional file 1:
Table S2 listing the expression states of all genes in specific
astrocytoma subsets. In addition, we have summarized
all discussed genes that were exclusively differentially
expressed in PA I, AS II, AS III or GBM IV in Table 1.
Selected genes exclusively observed in PA I Consid-
ering genes that were exclusively differentially expressed
in PA I, we observed several under- (e.g. EN2, EOMES,
MEIS1, NEUROD1, ZIC1, ZIC2, ZIC3, ZIC4) and overex-
pressed (e.g. EGR1, EGR3, OLIG1) TFs involved in brain
development. For example, EOMES is involved in neuron
division and/or migration [52]. Additionally, three known
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Table 1 Selected genes predicted to be differentially expressed in a specific astrocytoma grade
Gene Chromosome Band Expression Tumor Annotation
H3F3A 1 q42.12 - PA I H3 histone, family 3A
MEIS1 2 p14 - PA I Meis homeobox 1
NEUROD1 2 q31.3 - PA I neuronal differentiation 1
EOMES 3 p24.1 - PA I eomesodermin
ZIC1 3 q24 - PA I Zic family member 1
ZIC4 3 q24 - PA I Zic family member 4
EGR1 5 q31.2 + PA I early growth response 1
EN2 7 q36.3 - PA I engrailed homeobox 2
EGR3 8 p21.3 + PA I early growth response 3
CDKN2B 9 p21.3 + PA I cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
NTRK2 9 q21.33 + PA I neurotrophic tyrosine kinase, receptor, type 2
HIF1AN 10 q24.31 + PA I hypoxia inducible factor 1, alpha subunit inhibitor
SUV420H1 11 q13.2 - PA I suppressor of variegation 4-20 homolog 1 (Drosophila)
KRAS 12 p12.1 - PA I Kirsten rat sarcoma viral oncogene homolog
ZIC2 13 q32.3 - PA I Zic family member 2
SUZ12 17 q11.2 - PA I SUZ12 polycomb repressive complex 2 subunit
SUV420H2 19 q13.42 - PA I suppressor of variegation 4-20 homolog 2 (Drosophila)
OLIG1 21 q22.11 + PA I oligodendrocyte transcription factor 1
OLIG2 21 q22.11 + PA I oligodendrocyte lineage transcription factor 2
ATRX X q21.1 - PA I alpha thalassemia/mental retardation syndrome X-linked
ZIC3 X q26.3 - PA I Zic family member 3
FAM110C 2 p25.3 - AS II family with sequence similarity 110, member C
HEY2 6 q22.31 + AS II hes-related family bHLH transcription factor with YRPWmotif 2
NR2E1 6 q21 - AS II nuclear receptor subfamily 2, group E, member 1
EYA1 8 q13.3 + AS II EYA transcriptional coactivator and phosphatase 1
GAS2 11 p14.3 - AS II growth arrest-specific 2
DLL3 19 q13.2 + AS II delta-like 3 (Drosophila)
CDH4 20 q13.33 - AS II cadherin 4, type 1, R-cadherin (retinal)
SHROOM2 X p22.2 - AS II shroom family member 2
AP1AR 4 q25 - AS III adaptor-related protein complex 1 associated regulatory protein
CDC27 17 q21.32 - AS III cell division cycle 27
PPM1D 17 q23.2 + AS III protein phosphatase, Mg2+/Mn2+ dependent, 1D
ZNF24 18 q12.2 + AS III zinc finger protein 24
TXN2 22 q12.3 + AS III thioredoxin 2
AKT3 1 q44 - GBM IV v-akt murine thymoma viral oncogene homolog 3
MDM4 1 q32.1 + GBM IV MDM4, p53 regulator
PDGFRB 5 q32 + GBM IV platelet-derived growth factor receptor, beta polypeptide
VEGFA 6 p21.1 + GBM IV vascular endothelial growth factor A
EGFR 7 p11.2 + GBM IV epidermal growth factor receptor
FGFR1 8 p11.23 + GBM IV fibroblast growth factor receptor 1
FGFR2 10 q26.13 - GBM IV fibroblast growth factor receptor 2
BIRC3 11 q22.2 + GBM IV baculoviral IAP repeat containing 3
ERRB2 14 q24.3 + GBM IV nuclear receptor
NTRK3 15 q25.3 - GBM IV neurotrophic tyrosine kinase, receptor, type 3
BRCA1 17 q21.31 + GBM IV breast cancer 1, early onset
AKT2 19 q13.2 + GBM IV v-akt murine thymoma viral oncogene homolog 2
SMARCA4 19 p13.2 + GBM IV SWI/SNF related, matrix associated, actin dependent regulator of chromatin
Summary of discussed genes that were exclusively observed to be under- or overexpressed in a specific type of astrocytoma. The expression state of a gene in tumor is
specified by the ’Expression’ column with ’-’ representing underexpression and ’+’ representing overexpression in comparison to normal brain
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chromatin remodelers (SUV420H1, SUV420H2, SUZ12)
were underexpressed in PA I. In accordance with a recent
study [53], ATRX, a biomarker of adult astrocytomas,
was underexpressed in PA I. In contrast to AS III and
GBM IV, HIF1AN was strongly overexpressed in PA I.
Further, CDKN2B, a tumor suppressor for which overex-
pression has been reported to inhibit cell proliferation and
to cause senescence of glioma cells with intact RB pathway
[54], was overexpressed. OLIG2, which has been reported
to show increased expression in PA I and high-grade
gliomas [55], was overexpressed. NRTK2, which has been
reported to be highly expressed in low grade (WHO grade
I and II) gliomas [56], was overexpressed. Further, KRAS,
which plays an important role in cell cycle regulation, was
underexpressed. Additionally, H3F3A, which encodes for
a histone variant that is predominantly integrated into
chromatin of non-dividing cells, was underexpressed.
Selected genes exclusively observed in AS II In com-
parison to PA I and GBM IV, less genes were found to
be exclusively differentially expressed in AS II (Fig. 3a–b).
FAM110C, which has been reported to be part of a
stem cell-related self-renewal signature associated with
resistance to chemotherapy [57] and for which overex-
pression has been shown to promote cell cycle arrest in
rats [58], was underexpressed. CDH4, which encodes for
a cell-adhesion protein involved in brain segmentation
and neural outgrowth, was underexpressed. Underexpres-
sion of CDH4 is known to play a role in early tumor
progression of colorectal and gastric cancer [59]. NR2E1
(TLX), which is involved in anterior brain differentiation,
was underexpressed. Underexpression of NR2E1 has been
associated with cancer stem cell death and longer sur-
vival of G-CIMP glioma patients [60]. Further, SHROOM2
involved in cell spreading and GAS2 involved in apoptosis
were both underexpressed. The transcription factor HEY2
and the Notch ligand DLL3 both known for their func-
tions in neurogenesis and implicated in glioma biology
[61] were overexpressed. EYA1, which encodes for a phos-
phatase and transcriptional coactivator that is involved in
DNA repair and which has been associated with glioma
tumorigenesis [62], was overexpressed.
Selected genes exclusively observed in AS III Like for
AS II, only relatively few genes were exclusively differ-
entially expressed in AS III. Interestingly, PPM1D, which
is involved in p53-mediated cell cycle arrest, was over-
expressed. PPM1D gain-of-function mutations have been
reported for brain stem gliomas [63]. Additionally, a
PPM1D knock-down has been reported to inhibit prolif-
eration and invasion of glioma cells [64]. Further, AP1AR,
which negatively regulates cell spreading, size and motil-
ity, was underexpressed. CDC27 (APC3), which is part of
the anaphase promoting complex and which is involved
in timing ofmitosis, was underexpressed. Downregulation
of a related component (APC7) of the anaphase promot-
ing complex has been observed in breast cancer with
poor prognosis [65]. TXN2, which has been identified to
play an important role in the protection of osteosarco-
mas against oxidant-induced apoptosis [66], was overex-
pressed. Also ZNF24, which is involved in the mainte-
nance of progenitor cell states in the developing central
nervous system, was overexpressed. ZNF24 has further
been reported to be involved in the negative regulation of
angiogenesis [67].
Selected genes exclusively observed in GBM IV Many
known cancer genes (e.g. BIRC3, BRCA1, EGFR, ERRB2,
PDGFRB, VEGFA) were overexpressed in GBM IV. EGFR
signaling has been reported to contribute to radia-
tion and chemotherapy resistance of gliomas [68]. In
line with VEGFA overexpression, PDGFRB, which has
been reported to enhance glioma angiogenesis in tumor
endothelia by promoting pericyte recruitment [69, 70],
was overexpressed. Further, MDM4, which has been
observed to inhibit a p53-dependent growth control
[71, 72], was overexpressed. AKT2, for which under-
expression has been reported to induce apoptosis and
for which overexpression has been associated with
cell survival and invasion of more aggressive gliomas
[73, 74], was overexpressed. FGFR1, which has been
reported for its increased expression and associa-
tion with autocrine growth signaling in GBM IV
[75], was overexpressed. Further, SMARCA4, which
has been observed to have increased expression in
gliomas and which is potentially involved in control-
ling of cell proliferation, migration and invasion [76],
was overexpressed. PKG1, which has been reported
to promote radioresistance of glioma cells [77, 78],
was overexpressed. Further, AKT3, which has recently
been reported to inhibit vascular tumor growth [79], was
underexpressed. FGFR2, which is frequently found to be
underexpressed in primary GBM IV and which has been
associated with a poor clinical outcome [80], was under-
expressed. NTRK3, which has been reported to show
reduced expression in high-grade gliomas due to underly-
ing DNA methylation changes [81], was underexpressed.
Selected genes in the intersection of PA I, AS II, AS III
and GBM IV Genes commonly under- or overexpressed
in PA I, AS II, AS III and GBM VI were involved in cell
cycle regulation, differentiation, apoptosis and cell migra-
tion. We found that the cyclin-dependent kinase inhibitor
CDKN2D was underexpressed and CD44, HIF1A and
MAPKAPK3 were overexpressed in all four astrocytoma
grades. CD44 is a well-known stem cell marker that has
been reported to represent a potential therapeutic target
for glioblastoma [82]. HIF1A encodes the alpha subunit of
Seifert et al. BMC Cancer  (2015) 15:952 Page 11 of 22
the TF hypoxia-inducible factor-1 (HIF-1), which is one
of the master regulators of hypoxia response promoting
glioma growth and angiogenesis [83]. MAPKAPK3 is a
central integrator of mitogen and stress responses in dif-
ferent MAPK pathways [84]. Interestingly, RB1, a know
tumor suppressor controlling the progression through G1
into the S-phase of the cell cycle [85], was overexpressed.
Induction of wild-type RB1 has been reported to inhibit
tumor growth and tumorigenicity [86]. On the other hand,
inactivating mutations affecting the RB pathway have fre-
quently been observed in higher-grade gliomas [85]. This
potentially indicates that an overexpression of wild-type
RB1 in PA I may contribute to a reduced tumor growth,
whereas an exclusive overexpression of CDK4 in con-
cert with RB1 observed for AS II, AS III and GBM IV
may counteract the inhibition of tumor growth (see next
section for more details to CDK4).
Selected genes in the intersection of AS II, AS III
and GBM IV but not in PA I Genes commonly under-
or overexpressed in AS II, AS III and GBM IV were
enriched for cell-cell signaling, cell cycle, differentiation,
DNA repair, apoptosis and metabolism. Several known
oncogenes (e.g. ABL1, AKT1, MYC, NRAS) and tumor
suppressor genes (e.g. ATM, BCL10, TP53) were overex-
pressed in all three astrocytoma types. AKT1 has been
found to enhance proliferation and invasion of glioma
cells [87]. Overexpression of NRAS that increased with
glioma grade was observed in [88]. Overexpression and
different cellular locations of TP53 have been reported for
primary and secondary glioblastomas impacting on vas-
culature control and tumorigenesis [89]. Overexpression
of TP53 has also been associated with shorter progres-
sion free survival in malignant gliomas [90]. Further, also
CDK4 and RAF1 were overexpressed. CDK4 overexpres-
sion has been reported to induce hyperploidy and to
counteract senescence of cultured mouse astrocytes [91].
Astrocyte-specific overexpression of CDK4 in transgenic
mouse lines has been observed to provide cell growth
advantages in concert with TP53 pathway alterations [92].
Consecutive RAF1 activation has been reported to induce
glioma formation in mice [93]. Moreover, also IDH1 was
overexpressed. Interestingly, the overexpression of IDH1
in gliomas has recently been reported to have different
impacts on chemotherapy response. Wild-type IDH1 was
associated with resistance, whereas mutant-IDH1 showed
enhanced sensitivity to therapy [94]. MAP2K4, which
has been reported to inhibit tumor cell invasion in lung
cancer [95], was strongly underexpressed. Further, also
MAP2K1, which is involved in the regulation of many cel-
lular processes including proliferation, differentiation and
apoptosis, and also MKRN1, which has been observed
to stimulate apoptosis under stress conditions [96], were
both underexpressed.
Selected genes in the intersection of AS III and GBM
IV but not in PA I and AS II Genes commonly under-
or overexpressed in AS III and GBM IV were involved
in cell migration, cell cycle, DNA repair, chromatin orga-
nization, angiogenesis and metabolism. HIF1AN (FIH-
1), an inhibitor of the previously reported HIF-1, was
underexpressed. HIF1AN is involved in hypervascular-
ization and survival of glioma cells under hypoxic con-
ditions and may represent a potential therapeutic target
[97]. EZH2, a member of the polycomb-group family
involved in the control of DNA methylation [98] and
histone H3K27 trimethylation [99] over cell generations,
was overexpressed. Also VEGFB involved in blood ves-
sel survival [100] and CDC20 contributing to survival of
glioma initiating cells [101] were overexpressed. Further,
SOX2, amarker for undifferentiated and proliferating cells
observed to show expression levels that increase with the
glioma grade [102] and reported to regulate genes and
pathways associated with malignancy of stem-like and dif-
ferentiated glioma cells [103], was overexpressed. TACC3,
a potential oncogene overexpressed in a grade-specific
manner [104] and observed as fusion partner of FGFR3
in glioblastomas [105], was overexpressed. Moreover,
IDH2 was overexpressed. Interestingly, another study has
associated the overexpression of a point-mutated IDH2
(IDH2R172K) with increased radio sensitivity, reactive
oxygen metabolism, suppression of tumor growth and
migration in glioma cell lines compared to wild-type
IDH2 [106]. Thus, the underlying mutational status of
IDH2 may influence tumor aggressiveness of AS III and
GBM IV.
Transcriptional alterations of individual signaling
pathways typically increase with WHO grade
Next, we focused on individual cancer-relevant signal-
ing pathways and determined corresponding differentially
expressed genes for each type of astrocytoma. Figure 4
shows the numbers of overexpressed genes in known
cancer signaling pathways representing major differences
and some similarities between individual astrocytoma
types. We observed strong differences in the number of
overexpressed genes for nearly all pathways with grad-
ual increases from PA I to GBM IV. This trend was also
observed for the majority of signaling pathways consider-
ing underexpressed genes, except for the DNA replication
pathway and all DNA repair pathways that both only
showed very few or no underexpressed genes in all four
astrocytoma grades (Additional file 2: Figure S6). Focus-
ing on overexpression (Fig. 4), especially genes involved
in cell cycle, PI3K-AKT, TGF-Beta, focal adhesion, notch,
DNA replication and DNA repair pathways were signifi-
cantly affected by overexpression in AS II, AS III or GBM
IV. Genes involved in the regulation of apoptosis were
enriched in all four astrocytoma types.










































































































































































































































































































Fig. 4 Characteristic patterns of overexpression in signaling pathways distinguishing different astrocytoma grades. Number of overexpressed genes
in each known cancer-relevant signaling pathway are shown for each type of astrocytoma (PA I, AS II, AS III, GBM IV). Significant enrichment of
overexpressed genes in a pathway within a tumor type is highlighted by ’*’ (P < 0.05) and ’**’ (P < 0.01) (Fisher’s exact test)
Interestingly, the cytokine-cytokine receptor interaction
pathway did not not follow the general trend that the num-
bers of overexpressed genes systematically increased from
PA I to GBM IV. This pathway showed nearly the same
proportion of overexpressed genes in PA I as in GBM
IV, whereas the proportions of overexpressed genes in AS
II and AS III were consistently only approximately half
as large as for PA I and GBM IV (Fig. 4). This atypical
behavior also strongly contributed to significant exclusive
overlaps between PA I and GBM IV comparing under-
and overexpressed genes (purple subsets in Fig. 3c–d: 7
underexpressed genes with P < 6.2×10−6 and 33 overex-
pressed genes with P < 1.7×10−8, Fisher’s exact test). We
additionally note that the p53 pathway and the Jak-STAT
pathway showed both a very similar behavior compara-
ble to those of the cytokine-cytokine receptor pathway
(Fig. 4).
Highly overlapping expression patterns of
cytokine-cytokine receptor interaction pathway between
PA I and GBM IV, but only GBM IV is enriched for known
cancer genes
We observed similar proportions of overexpressed genes
in the cytokine-cytokine receptor interaction pathway
for PA I and GBM IV (Fig. 4). Cytokines are intracel-
lular signaling proteins that are important regulators of
immune response, cell growth, differentiation, metastasis,
apoptosis and angiogenesis [107–109]. Some alterations
of expression levels of specific cytokines, their corre-
sponding receptors and links to their potential role in
brain tumor development have already been reported for
benign and malignant astrocytomas more than a decade
ago [110–112]. In addition, different chemokines and
chemokine receptors were found to contribute to glioma
cell survival, migration and invasion [113–118]. We there-
fore focused on individual genes in the cytokine-cytokine
receptor interaction pathway to provide a comprehen-
sive overview of differentially expressed genes comparing
PA I and GBM IV. A representation of the cytokine-
cytokine receptor interaction pathway highlighting exclu-
sively affected and commonly altered genes is shown
in Fig. 5. We found a significant overlap of commonly
observed under- and overexpressed genes in the cytokine-
cytokine receptor interaction pathway comparing PA I
and GBM IV (overlap: 20 genes, 1 underexpressed, 19
overexpressed genes, P < 2.5 × 10−42, Fisher’s exact
test). We further identified genes that were only differen-
tially expressed in PA I (1 under- and 20 overexpressed
genes) or in GBM IV (5 under- and 24 overexpressed
genes) alone. Only genes that were exclusively overex-
pressed in GBM IV were significantly enriched for known
cancer genes [45] (P < 4.2 × 10−5, Fisher’s exact test).
These genes were mainly assigned to the CXC chemokine,
hematopoietin, PDGF or TGF-Beta pathway subfamilies
of the cytokine-cytokine receptor interaction pathway
(Fig. 5). This included genes such as EGFR, PDGFRB,
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Fig. 5 Transcriptional alterations of cytokine-cytokine receptor interaction pathway genes comparing PA I and GBM IV. Representation of under-
and overexpressed cytokine-cytokine receptor interaction pathway genes identified in PA I and GBM IV in comparison to normal brain tissue. The
basic pathway map (hsa:04060) was generated using KEGG [130] and manually modified. Genes are colored according to their observed expression
level (i) genes only overexpressed in PA I (light blue), (ii) genes only underexpressed in GBM IV (red), (iii) genes only overexpressed in GBM IV (orange),
(iv) genes commonly overexpressed in PA I and GBM IV (grey), except for KIT that was underexpressed in both tumor types, (v) CX3CL1
overexpressed in PA I and underexpressed in GBM IV (green), (vi) genes that were not present on the microarray (purple), and (vii) genes with
unchanged expression levels (white)
TNFRSF14 or VEGFA previously associated with aggres-
siveness, invasion and poor outcome of GBM IV
[25, 119, 120].
Differences in CX3CL1 expression between PA I and AS II,
AS III and GBM IVmay contribute to absence or presence of
glioma cell invasion
Interestingly, CX3CL1 (also known as fractalkine or neu-
rotactin), a member of the cytokine-cytokine receptor
interaction pathway (Fig. 5) encoding for a chemokine,
showed a characteristic expression pattern distinguish-
ing PA I from AS II, AS III and GBM IV (Additional
file 1: Table S2). The soluble form of the CX3CL1 pro-
tein is a potent chemoattractant of T-cells and mono-
cytes, while the cell-surface-bound form promotes strong
adhesion of those leukocytes [121]. CX3CL1 implements
its adhesive and migratory functions by interacting with
the chemokine receptor CX3CR1 [122]. The roles of
CX3CL1 and CX3CR1 in glioma invasion and progres-
sion have been reviewed for malignant astrocytomas in
[117]. Potential contributions of both genes to suppress an
invasive phenotype in PA I have not been studied so far.
We found that CX3CL1 and CX3CR1 were overex-
pressed in PA I in comparison to normal brain tissue,
whereas we further observed strong underexpression of
CX3CL1 and unchanged expression of CX3CR1 in AS
II, AS III and GBM IV (Additional file 1: Table S2). In
accordance, CX3CR1 has been reported to be expressed
in gliomas [123], and CX3CL1 has been reported to
reduce neuronal migration by increasing cell adhesion
[124]. Potentially, a similar CX3CL1-induced mechanism
in PA I may contribute to the absence of infiltrative
growth typically observed for AS II, AS III and GBM IV
[125]. This hypothesis is supported by the finding that the
inhibition of CX3CL1 strongly increased glioma cell inva-
sion suggesting that functionally active CX3CL1 counter-
acts an invasive phenotype [116]. Additionally, they also
reported that TGFB1 negatively influenced the expression
of CX3CL1 facilitating glioma cell detachment and dis-
persion. In agreement with our hypothesis, the expression
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levels of CX3CL1 were negatively correlated with those
of TGFB1 (r = −0.98, P < 0.01). We observed overex-
pression of TGFB1 in AS II, AS III and GBM IV, whereas
TGFB1 expression was unchanged in PA I in comparison
to normal brain tissue (Additional file 1: Table S2).
A transcriptional signature distinguishes PA I from AS II, AS
III and GBM IV
Besides some similarities, our previous studies clearly
indicated the existence of systematic differences between
PA I and AS II, AS III and GBM IV supporting the find-
ing that both classes represent different pathobiological
entities [126]. To further investigate this, we determined
a molecular signature comprising 1,089 differentially
expressed genes distinguishing PA I from AS II, AS III and
GBM IV (Fig. 6, Additional file 1: Table S3). This signa-
ture included all under- and overexpressed genes from PA
I that did not show the same expression state in AS II,
AS III or GBM IV. Vice versa, this signature also included
each gene that was identified as under- or overexpressed
in AS II, AS III or GBM IV but which did not show the
same expression state in PA I. Clusters of genes that were
under- or overexpressed in one class but not in the other
are clearly visible characterizing differences between PA
I and AS II, AS III and GBM IV (Fig. 6). A gene annota-
tion analysis (Additional file 1: Table S3) further revealed
that nearly 14% of the signature genes were annotated as
TFs (151 of 1,089), about 10% were part of known cancer-
relevant signaling pathways (111 of 1,089), about 5% were
known cancer genes (55 of 1,089) and about 3% were part
of metabolic pathways (34 of 1,089).
A regulatory network is associated with expression
differences between PA I and AS II, AS III and GBM IV
Next, we used the 151 differentially expressed TFs from
the molecular signature (Fig. 6, Additional file 1: Table S3)
−10 −5 0 5 10
PA I AS II
     
AS III GBM IV
Gene Expression:            Log−Ratio(Tumor / Normal)
Gene Type: Transcription Factor Pathway Gene Both
Fig. 6Molecular signature distinguishing PA I from AS II, AS III and GBM IV. The heatmap shows the expression levels of 1,089 genes (rows) with
strong expression differences between PA I and AS II, AS III and GBM IV for individual tumor patients (columns). Expression levels are displayed as
log-ratios comparing gene expression levels in tumor to normal brain. Underexpressed genes are displayed in blue, unchanged expressed genes in
grey, and overexpressed genes are displayed in red. Genes were clustered according to their similarity of expression levels across all tumor samples.
The color code at the left side highlights genes that are TFs (purple), signaling pathway genes (green), or both (brown)
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to learn a transcriptional regulatory network that best
explained expression changes of all signature genes dis-
tinguishing PA I from AS II, AS III and GBM IV (Fig. 7,
Additional file 1: Table S4). This network contained for
each individual signature gene those TFs that may act
as putative regulators of this gene. The regulatory net-
work was extremely sparse containing only 1,558 out of
164,439 theoretically possible regulatory links from TFs
to signature genes. We observed more than three times
more activator than repressor links in the network (1,195
vs. 363). Nine TFs did not have any outgoing regulatory
links to other signature genes, and no putative regulators
were identified for 83 signature genes.
Still, as expected, the obtained regulatory network was
highly predictive for the expression levels of signature
genes in our astrocytoma data set used to learn the net-
work (Additional file 2: Figure S7a). We further used
the obtained regulatory network to predict expression
changes of signature genes in three independent brain
tumor cohorts (41 PA I from [46], 465 low grade gliomas
including 50 AS II and 104 AS III from TCGA LGG, 553
GBM IV from TCGA GBM [23], see Additional file 2:
Text S4 for details). We observed that the regulatory net-
work was very predictive for the vast majority of signature
genes (Additional file 2: Figures S7b–d). We also analyzed
the proportion of putative direct TF-target gene interac-
tions by comparing predicted target genes of TFs in the
regulatory network to target genes predicted by TF-based
motif search in promoter sequences of signature genes
(see Additional file 2: Text S5 for details).We observed sig-
nificant overlaps of network- andmotif-based target genes
for many TFs, but there were also TFs with only little or
no overlaps (Additional file 2: Figure S8). All these tests
indicated that the regulatory network contained relevant
TF-target gene links to enable the prediction of signature
gene expression levels.
Expression changes of hub regulators characterize
differences between PA I and AS II, AS III and GBM IV
We next utilized the obtained signature-specific regu-
latory network to identify central hub TFs with many
outgoing links to other signature genes. These hub regula-
tors are represented by large nodes in Fig. 7. The majority
of these TFs had on average lower expression levels in
AS II, AS III and GBM IV than in PA I (blue nodes).
A smaller proportion of hub TFs had higher expression
levels in AS II, AS III and GBM IV than in PA I (red
nodes). Many of these hub TFs were part of three major
functional categories: (i) TFs involved in apoptosis, cell
proliferation, cell cycle andDNA repair (CCNA2, CCNB1,
CCNB2, CDC20, CHD5, GPR123, MEF2C, NEUROD1,
VIP, ZNF365), (ii) TFs involved in chromatin remodel-
ing, histone modifications and DNA methylation (CHD5,
DNMT1, EZH2, JARID2), and (iii) TFs involved in
brain development and differentiation (ARNT2, CHD5,
DNMT1, ELF1, EOMES, HLF, JARID2, LHX1, MEF2C,
NEUROD1, OLIG1, SOX10, SOX11, THRB, TBR1, VIP,
ZIC1, ZIC3).
Next, we studied the hierarchy of TFs in the regulatory
network to identify signature-specific hub TFs that had
many regulatory links to other TFs. We found that several
TFs had clearly increased numbers of outgoing links to
other TFs (Additional file 2: Figure S9). Six TFs had more
than five outgoing regulatory links to other TFs (CCNL2,
GPR123, ZCCHC24, TBR1, ZNF300, ZNF337). CCNL2
encodes for a cyclin involved in the regulation of splic-
ing, apoptosis and cell growth [127]. GPR123 is a member
of the adhesion family of G-protein coupled receptors
mutated in leukemia [128]. TBR1 encodes for a T-box
TF required for normal brain development expressed in
post-mitotic cells [129]. Nothing was known in the lit-
erature about the functions of ZCCHC24, ZNF300 and
ZNF337 so far. We analyzed their network-target genes
to learn more about their putative functions. This sug-
gested that ZCCHC24 is involved in the regulation of the
cell cycle and of cell-cell interactions. ZNF300 might act
on developmental processes impacting on DNA and his-
tone methylation patterns. ZNF337 might contribute to
genomic and epigenomic integrity.
Mutations affecting TFs contribute to differences between
PA I and AS II, AS III and GBM IV
To further characterize how genomic and epigenomic
mutations may have contributed to expression differences
of TFs between PA I andAS II, AS III andGBM IV, we ana-
lyzed the individual signature-specific TFs for alterations
of DNA methylation levels or gene copy number muta-
tions in comparison to normal tissue. Gene copy number
mutations are typically absent in PA I, but changes of DNA
methylation patterns within gene bodies or up- and down-
stream of transcription start sites have been reported [38].
In contrast to PA I, deletions and amplifications of indi-
vidual genes are typically present in AS II, AS III and GBM
IV [40]. DNA methylation profiles were available for the
majority of our PA I tumors (38 of 47) and gene copy num-
ber profiles were available for all our AS II, AS III and
GBM IV tumors. We therefore analyzed the expression
of individual signature-specific TFs in relation to directly
underlying mutations (Fig. 8).
We found for PA I that TFs with altered expression
and/or altered DNA methylation levels were part of three
major functional categories (Fig. 8a): (i) TFs involved
in development and differentiation (e.g. EN2, EOMES,
DMRT2, NR0B1), (ii) TFs involved in cell cycle con-
trol, proliferation and apoptosis (e.g. CDC20, NFKBIZ,
ZCCHC24), and (iii) TFs involved in chromatin remod-
eling and DNA methylation (ESRRG, L3MBTL4, SATB2).
Several TFs were strongly under- or overexpressed in
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Fig. 7 Transcriptional regulatory network distinguishing PA I from AS II, AS III and GBM IV. TFs are displayed by labeled circles. The circle size
increases with the number of outgoing regulatory edges to other signature genes highlighting major regulators by large circles. The color coding of
the circle represents the average expression level of the corresponding gene in AS II, AS III and GBM IV diagnosed in adults relative to PA I diagnosed
in children and young adults: underexpressed (blue) and overexpressed (red) in adult astrocytomas. Inferred regulatory dependencies between TFs
and signature genes are displayed by directed edges: activator (orange) and repressor (purple)
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Fig. 8 Epigenomic and genomic mutations associated with TF expression changes distinguishing PA I from AS II, AS III and GBM IV. TFs are displayed
by circles. The circle size increases with the number of outgoing regulatory edges to other signature genes highlighting major regulators by large
circles. Names of TFs strongly deviating from the center are shown in black. TFs belonging to selected annotation categories are highlighted by
colored circles. Gene-specific changes in expression, DNA methylation or copy number are quantified by log-ratios comparing tumor to normal
brain tissue. A log-ratio close to zero indicates no change in tumor, whereas a strong deviation from zero indicates a change. a, Average DNA
methylation changes associated with TFs plotted against their average expression profiles in PA I. b, Average copy changes of TFs plotted against
their average expression profiles in AS II, AS III and GBM IV
PA I without strong directly underlying DNA methy-
lation changes (e.g. EGR2, INSM1, LHX1, NEUROD1).
None of the central hub TFs in Fig. 7 showed strong
expression changes in PA I in response to directly under-
lying DNA methylation changes, except for CDC20 and
ZCCHC24. Other TFs with fewer outgoing links to sig-
nature genes showed greatly altered expression levels in
PA I in response to strong DNAmethylation changes (e.g.
EGR3, EN2, EOMES, NR0B1, PAX6, SATB2, ZIC1, ZIC2,
ZIC3, ZIC4).
This situation was quite different for AS II, AS III and
GBM IV (Fig. 8b). Four central hub TFs showed strongly
altered expression levels in response to directly under-
lying gene copy number mutations (CDC20, GPR123,
ZNF365, ZNF488), whereas other hub TFs showed
strong underexpression without underlying deletions
(e.g. CHD5, HLF, TBR1, THRB, VIP). Again, TFs with
altered expression and/or copy number mutations were
part of three major functional categories as observed
for PA I before. The majority of TFs was involved
in development and differentiation (e.g. EGR2, EMX2,
DACH2, MEOX2, SOX11). Other TFs were involved in
cell cycle control, proliferation, apoptosis and DNA repair
(e.g. CCNA1, CDC20, CHD5, TP53, ZNF365). Some TFs
were involved in the regulation of chromatin remod-
eling and DNA methylation (CHD5, EZH2, PAXIP1,
ZNF300).
Conclusions
Our computational study revealed similarities and dif-
ferences in gene expression levels between astrocytomas
of all four WHO grades under consideration of astro-
cytoma type-specific normal brain references. We com-
pared all four considered astrocytoma grades (PA I, AS
II, AS III, GBM IV) at the level of individual genes and
cancer-relevant signaling pathways. Thereby, we identi-
fied many genes that were exclusively under- or over-
expressed in a specific astrocytoma grade. In addition,
we also revealed many genes that showed the same pat-
tern of under- or overexpression in specific subsets of
astrocytoma grades. We discussed many of these genes
in the background of the currently existing literature and
we summarized selected astrocytoma type-specific dif-
ferentially expressed genes that might be of interest for
future studies that aim at the development of novel mark-
ers. We further observed at the level of individual genes
and cancer-relevant signaling pathways that the num-
ber of differentially expressed genes typically increased
with the astrocytoma grade. This trend suggests an asso-
ciation of transcriptional alterations with the increased
tumor aggressiveness of the different astrocytoma grades.
Interestingly, the cytokine receptor interaction pathway
escaped this general trend. Nearly the same number of
overexpressed genes were observed for PA I and GBM
IV in this pathway. Detailed studies further identified
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commonly and exclusively overexpressed genes in the
cytokine receptor interaction pathway for PA I and GBM
IV and further revealed that only genes that were over-
expressed in GBM IV were significantly enriched for
known cancer genes involved in aggressiveness, invasion
and poor outcome. Moreover, this in-depth analysis also
revealed a characteristic expression patterns of CX3CL1
(fractalkine) and its receptor CX3CR1 that distinguished
PA I from AS II, AS III and GBM IV. These genes are
involved in glioma invasion and progression of malignant
astrocytomas [117]. Strong overexpression of both genes
in PA I in comparison to higher grade astrocytomas sug-
gests a potential contribution to the non-invasive growth
behavior of PA I. Thus, it might be worth to validate this
potential link by gene knockdowns in a future study.
Surprisingly, PA I was strongly associated with the mes-
enchymal subtype, which is typically observed for very
aggressive GBM IV. Additional analyses indicated that the
tumor micro-environment may have a greater contribu-
tion to the manifestation of the mesenchymal subtype
than the tumor biology itself, which might explain the
seemingly contradiction between the similarity in terms of
subtype classification and the very different clinical course
of mostly benign PA I and highly malignant GBM IV. In
accordance with this, we found that the endothelial cell
marker ANGPT2 (alias ANG2) was highly overexpressed
in PA I and GBM IV but not in AS II or AS III. Using
immunohistochemistry, we confirmed that PA I and GBM
IV showed Ang2-positive endothelial cells in regions with
activated blood vessels. This feature was largely absent in
AS II and AS III. Thus, our study suggests that microvas-
cular proliferation and necrosis, which both have been
described as common histological features of PA I and
GBM IV [8], contribute at least to some extent to the
observation of the mesenchymal subtype.
We also revealed major transcriptional regulators that
distinguished PA I from AS II, AS III and GBM IV based
on a computationally inferred signature-specific tran-
scriptional regulatory network.We found that many of the
differentially expressed central transcriptional regulators
play important roles in cell cycle regulation, chromatin
remodeling, or brain development and differentiation.
Further analyses indicated that the differential expression
of transcriptional regulators was mainly driven by directly
underlying DNAmethylation changes in PA I or gene copy
number alterations in AS II, AS III and GBM IV. We note
that the impacts of DNA methylation changes on tran-
scriptional regulators in AS II, AS III and GBM IV could
not be compared to those in PA I, because DNA methyla-
tion profiles were not available for AS II, AS III and GBM
IV tumors from Rembrandt. This could be addressed in
a future study using DNA methylation profiles measured
for AS II, AS III and GBM IV from TCGA brain tumor
cohorts.
We are aware that our network approach can also be
utilized for the analysis of a molecular signature that
distinguishes all four astrocytoma types. However, this
should be done based on a larger data set including
additional astrocytoma samples from other resources to
ensure robustness and transferability. A future study could
for example utilize additional publicly available astro-
cytoma data sets (e.g. TCGA and ICGC data sets and
other smaller studies) and further try to directly integrate
additional omics layers (e.g. gene copy numbers, DNA
methylation profiles, single nucleotide polymorphisms).
Altogether, our study confirmed many known findings
and revealed novel interesting insights into astrocytoma
biology and therefore represents a valuable resource for
future studies.
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